“Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults.”, Vaccine, vol. 20, no. 7-8, pp. 1099-105, 2002.
, “Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains.”, J Infect Dis, vol. 192, no. 12, pp. 2092-8, 2005.
, “Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults.”, J Infect Dis, vol. 193, no. 9, pp. 1223-8, 2006.
, “Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.”, N Engl J Med, vol. 354, no. 13, pp. 1343-51, 2006.
, “Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.”, J Infect Dis, vol. 198, no. 5, pp. 635-41, 2008.
, “A phase III equivalence trial of azithromycin versus benzathine penicillin for treatment of early syphilis.”, J Infect Dis, vol. 201, no. 11, pp. 1729-35, 2010.
, “Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults.”, Vaccine, vol. 29, no. 34, pp. 5666-74, 2011.
, “Immunogenicity of an inactivated monovalent 2009 H1N1 influenza vaccine in pregnant women.”, J Infect Dis, vol. 204, no. 6, pp. 854-63, 2011.
, “Predictors of serological cure and Serofast State after treatment in HIV-negative persons with early syphilis.”, Clin Infect Dis, vol. 53, no. 11, pp. 1092-9, 2011.
, “Safety and immunogenicity of a candidate parvovirus B19 vaccine.”, Vaccine, vol. 29, no. 43, pp. 7357-63, 2011.
, “Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant.”, J Infect Dis, vol. 203, no. 5, pp. 666-73, 2011.
, “Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009.”, Vaccine, vol. 30, no. 28, pp. 4240-8, 2012.
, “Rapid plasma reagin titer variation in the 2 weeks after syphilis therapy.”, Sex Transm Dis, vol. 39, no. 8, pp. 645-7, 2012.
, “Safety and immune responses in children after concurrent or sequential 2009 H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.”, J Infect Dis, vol. 206, no. 6, pp. 828-37, 2012.
, “First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001).”, J Infect Dis, vol. 207, no. 2, pp. 240-7, 2013.
, “Response to therapy following retreatment of serofast early syphilis patients with benzathine penicillin.”, Clin Infect Dis, vol. 56, no. 3, pp. 420-2, 2013.
, “Clinical and immune responses to inactivated influenza A(H1N1)pdm09 vaccine in children.”, Pediatr Infect Dis J, vol. 33, no. 8, pp. 865-71, 2014.
, “First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002).”, J Infect Dis, vol. 210, no. 7, pp. 1052-61, 2014.
, “Impact of body mass index on immunogenicity of pandemic H1N1 vaccine in children and adults.”, J Infect Dis, vol. 210, no. 8, pp. 1270-4, 2014.
, “Safety and efficacy assessment of two new leprosy skin test antigens: randomized double blind clinical study.”, PLoS Negl Trop Dis, vol. 8, no. 5, p. e2811, 2014.
, “Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans.”, J Infect Dis, vol. 211, no. 4, pp. 518-28, 2015.
, “Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.”, Vaccine, vol. 33, no. 1, pp. 163-73, 2015.
, “Randomized trial comparing the safety and antibody responses to live attenuated versus inactivated influenza vaccine when administered to breastfeeding women.”, Vaccine, vol. 36, no. 31, pp. 4663-4671, 2018.
, “Safety and immunogenicity of seasonal trivalent inactivated influenza vaccines in pregnant women.”, Vaccine, vol. 36, no. 52, pp. 8054-8061, 2018.
,